Immuneering financials
$4.13−0.72%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $317.0K | $2.1M |
| Gross profit | $0.00 | $0.00 | $0.00 | $158.8K | $926.9K |
| Gross margin | — | — | — | 50.1% | 44.6% |
| Operating income | -$59.4M | -$64.1M | -$58.4M | -$51.7M | -$33.9M |
| Net income | -$56.0M | -$61.0M | -$53.5M | -$50.5M | -$33.5M |
| Net margin | — | — | — | −15937.3% | −1612.3% |
| Diluted EPS | $-1.27 | $-2.04 | $-1.88 | $-1.91 | $-2.46 |
| EBITDA | -$59.0M | -$63.7M | -$58.1M | -$50.9M | -$33.7M |
| Operating cash flow | -$45.3M | -$55.0M | -$49.0M | -$44.1M | -$30.9M |
| Free cash flow | -$45.5M | -$55.1M | -$49.3M | -$44.8M | -$30.9M |
| Diluted shares | 44.0M | 30.0M | 28.4M | 26.4M | 13.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $128.6M | $36.1M | $59.4M | $72.6M | $74.9M |
| Short-term investments | $44.2M | $0.00 | $26.3M | $32.9M | $74.3M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $232.0M | $52.7M | $102.6M | $122.4M | $166.7M |
| Total liabilities | $13.5M | $11.3M | $12.0M | $12.5M | $10.7M |
| Shareholders' equity | $218.5M | $41.4M | $90.6M | $109.9M | $156.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology